Prenatal beta-2-adrenergic agonist exposure linked to increased ASD risk with aOR 1.34 preconception

This systematic review and meta-analysis examined the impact of prenatal exposure to asthma medications on neurodevelopmental and educational outcomes in offspring. The study population comprised 3,867,170 individuals, including pregnant women and their children. The analysis focused on exposure to beta-2-adrenergic agonists and inhaled corticosteroids. The primary outcome assessed included autism spectrum disorder, attention-deficit hyperactivity disorder, and other developmental metrics. Secondary outcomes evaluated communication skills, motor skills, problem-solving abilities, personal-social skills, and cerebral palsy incidence. The setting of the included studies was not reported in the source data. The comparator for the primary analysis was not reported in the provided JSON input.

The primary results indicated a significant association between exposure to beta-2-adrenergic agonists and autism spectrum disorder. The analysis showed an adjusted odds ratio of 1.34 for exposure preconception and an adjusted odds ratio of 1.29 for exposure during pregnancy. The absolute numbers for the autism spectrum disorder outcome were n = 1,380,871. The 95% confidence interval for preconception exposure was [1.19,1.52], and the 95% confidence interval for exposure during pregnancy was [1.16,1.42]. Both intervals indicate an increased risk direction. An association with attention-deficit hyperactivity disorder was reported in a single study. Specific effect sizes, absolute numbers, p-values, or confidence intervals for ADHD were not reported in the source data.

Safety and tolerability findings were not reported in the provided data. Adverse events, serious adverse events, discontinuations, and general tolerability were not reported. The study did not provide data on specific adverse event rates or discontinuation reasons. The limitations of this meta-analysis include residual confounding and exposure misclassification. The analysis did not adequately distinguish between medication effects and underlying maternal asthma. Additionally, few number of studies were included in the meta-analysis. These factors contribute to uncertainty regarding the causal nature of the observed associations.

Comparison to prior landmark studies in this therapeutic area was not detailed in the source text. The review notes that the association with ADHD requires corroboration. The certainty of the evidence was not reported in the input data. The study design is a systematic review and meta-analysis. The publication type is a systematic review and meta-analysis. The study phase is not reported. Funding or conflicts of interest were not reported.

Clinical implications suggest caution when interpreting these results. The association between prenatal exposure to beta-2-adrenergic agonists and ASD is noted. The association with ADHD remains unconfirmed. Clinicians must consider that the observed links may reflect underlying maternal asthma rather than drug toxicity. Questions remain unanswered regarding the specific mechanisms of action. Further research is needed to clarify the role of these medications in neurodevelopment. The data does not support claims of causation beyond the reported associations. Practice relevance was not reported in the source material. The findings highlight the need for careful interpretation of observational data in asthma management during pregnancy.